Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedT-Cell Prolymphocyte LeukemiaSubgroupCD30+JAK2 rearrangementTP53 mutationICD10C82.-C82.7C82.9C83.3C84.0C84.4C84.5C84.6C84.7C84.8C85.2C86.1C86.2C86.5C91.5-C91.6-C94.7-MeSHImmunoblastic LymphadenopathyLeukemia, Prolymphocytic, T-CellLymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMycosis FungoidesSequenceCHOP (CYCL750/DOXO50/VNCR2/PRED60)/AZCT300, T-NHL, C1 (PID2762) -|- CHOP (CYCL750/DOXO50/VNCR2/PRED60)/AZCT300, C2-6 (PID2763)GUIDANCE-03: CHOP 21 (CYCL750/DOXO50/VNCR2/PRED100), T-NHL (PID1799) -|- CHOP (CYCL750/DOXO50/VNCR2/PRED60)/DECI10, C2-6 (PID2760) or CHOP (CYCL750/DOXO50/VNCR2/PRED60)/AZCT100, C2-6 (PID2761)STUDY - levelChemotherapyChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDecitabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDecitabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDecitabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineChemo-substanceAzacitidineBrentuximab vedotinCarboplatinCisplatinCyclophosphamideDecitabineDexamethasoneDoxorubicinEtoposideGemcitabineIfosfamideNivolumabOxaliplatinPrednisoloneRuxolitinibVincristineNo. Substances12345 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFosaprepitantGranisetronMagnesium sulfateMesnaPegfilgrastimPotassium chlorideNo. Substances123467Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHypocalcemiaHyponatremiaIncrease AminotransferasesInfectionsMucositisNeuropathyNeutropeniaPneumoniaPyrexiaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorCai MCDupuis JHeld GHorwitz SMoskowitz AJ Qi FRuan JSimon AVan de Wyngaert ZZinzani PLDiseasePeripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2Peripheres T-Zell Lymphom, Erstlinie, ECOG 0-2peripheres T-Zell Lymphom, Zweitlinie nach CHOP, ECOG 0-2Peripheres T-Zell Lymphom oder Mykosis fungoides, mindestens 2 Vortherapienrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3T-Zell-Lymphom, ECOG 0-2T-Zell-Lymphom, TET2/KMT2D mutiert, ECOG 0-2T-Zell-Lymphom, TP53 mutiert, ECOG 0-2T-Zell Lymphom, Erstlinie, ECOG 0-2T-Zell Lymphom rezidiviert oder therapierefraktär, ECOG 0-3OriginCentre Hospitalo-Universitaire (CHU) Grenoble, GOELAMS-LTP95 trialDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), BeijingGroupe hospitalo-universitaire Chenevier Mondor, Creteil, France, ORACLE trialHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceInstitute of Hematology and Medical Oncology, University of Bologna, Bologna, ItalyInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Memorial Sloan-Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupMemorial Sloan Kettering Cancer Center, New York, NY, USA, ECHELON-2Ruijin Hospital Af liated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, GUIDANCE-03 trialWeill Cornell Medicine and New York Presbyterian Hospital, New York, USAProtocols in Revision 16 protocols foundAzacitidine 300, T-cell Lymphoma (PID2688 V1.0)BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)CHOP (Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 60) / Azacitidine 100, T-cell Lymphoma, cycle 2-6 (PID2761 V1.0)CHOP (Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 60) / Azacitidine 300, T-cell Lymphoma, Cycle 1 (PID2762 V1.0)CHOP (Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 60) / Azacitidine 300, T-cell Lymphoma, cycle 2-6 (PID2763 V1.0)CHOP (Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 60) / Decitabine 10, T-cell Lymphoma, cycle 2-6 (PID2760 V1.0)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma (PID1799 V1.0)CHOP 21 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, T-cell Lymphoma, Variant 1 (PID1773 V1.1)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)GDP - Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 25, T-cell Lymphoma (PID2435 V1.0)Gemcitabine 1200, T-cell Lymphoma (PID1924 V1.0)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
